• Locations
  • Conditions
  • Treatments
  • Institutions
  • Resources
  • For researchers
  • About us
Facebook link logoLinkedin link logo
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
LocationsTexasArizonaCaliforniaNew YorkMassachusettsFloridaNew JerseyUtahAll locationsConditionsOncologyAlzheimer'sDiabetesMultiple SclerosisArthritisHepatitis CCOPDDepressionAll conditionsTreatmentsWeight LossStem CellsVaccinesSleep ApneaMedical DevicesIVFDentalDrug AddictionAll treatmentsInstitutionsPfizerModernaNIHUCLAStanfordM.D. AndersonLabcorpAll institutionsResourcesBlogFAQMedical advisors
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
  1. Clinical trials
  2. Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
  3. Apply

QuizartinibEvaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Basic information
Step 1/5

Provide your basic information